Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Vidac Pharma Holding plc reports preclinical proof of principle
Vidac Pharma Holdings plc will report promising results for its cancer drug candidate VDA-1275 in multiple mouse cancer and human cellular...
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
Naobios and Sumagen partner to develop HIV vaccine
Under the contract, Naobios SAS will provide bioprocess development and GMP production of clinical batches of a virus-based HIV vaccine candidate...
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...